Cardiac Transplant Metabolomics With and Without Rejection
ConditionHeart Transplant Rejection
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWestern University, Canada
About this trial
Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection. The purpose of this research study is to identify novel metabolic biomarkers that can be developed into a blood test that can identify signs of rejection without doing a heart biopsy.
Eligibility criteria
Qualifiers
All patients with heart transplant undergoing routine endomyocardial biopsy and blood work for transplant rejection screening and workup.
Patients or substitute decision makers are able to provide informed consent to agree to participate in this study.
Disqualifiers
Patients or substitute decision makers declined to participate in this study.
Trial design
Treatments tested in this trial
- Extra blood samples (5-10 mL) drawn
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Western University, Canada
Lead sponsor
Canadian Cardiovascular Society
Collaborator
Bayer
Collaborator
University of Alberta
Collaborator
Queen's University
Collaborator
Source ClinicalTrials.gov